MDC Annual Neuromuscular ‘Seed Grant’ Competition Launch
MDC is very excited to announce that their Annual Neuromuscular ‘Seed Grant’ Competition has launched and are now accepting applications until Feb 2, 2021 for Translational Science Seed Grants and Clinical Health Management Grants.
During a time when health research funding is challenged due to the COVID-19 pandemic and as many like-minded organizations/agencies have had to cancel their research competitions, MDC are very grateful that they are able to continue the momentum achieved over the last several years and provide critical research funds to help accelerate the understanding of neuromuscular disorders, identify pathways for future therapies and optimize care to improve the quality of life for Canadians affected by neuromuscular disorders
For information on the scope and guidelines of this year’s competition, please visit:
https://muscle.ca/researchers/funding-guideline-deadlines/
Applications with cross-cutting applicability to multiple neuromuscular disorders under MDC’s umbrella as well as disorder-specific ones are welcomed. Special consideration will be given to relevant meritorious applications in the following disease-specific areas, through designated funds generously provided by donors: Myotonic Muscular Dystrophy, Facioscapulohumeral Muscular Dystrophy, Immune-mediated Myopathies, Charcot-Marie-Tooth Disease, Pediatric Neuromuscular Disorders.
The total budget per project is $60,000 for 2 years.
Key Dates:
Full Application Deadline: February 2 at 11:59 pm (EST)
Notice of Decision: April 2020
Funding Start Date: May 1, 2020
All applications are available online at proposalCENTRAL.
Read next...
NMD4C Receive Excellence in Service Delivery Award and Network Investigators Honored as part of Muscular Dystrophy Canada’s 2024 Dr David Green Awards
We are excited to share that the NMD4C has been awarded the Excellence in Service Delivery Award, one of the annual Dr David Green Awards presented by Muscular Dystrophy Canada.
NMD4C Launch Canadian Neuromuscular Clinical Trial Network
We are thrilled to announce the launch of a Canadian neuromuscular clinical trial network (CTN) as a part of our clinical research work.
Training Session for Physiotherapists and Occupational Therapists on Outcome Measures in Spinal muscular atrophy hosted by Quebec SMA Network
This past March 23, the Quebec SMA Network (Réseau québécois de l’amyotrophie spinale – RQAS) in collaboration with the NMD4C and Muscular Dystrophy Canada (MDC) hosted an interactive training session for French-speaking physiotherapists and occupational therapists on assessment measures and practices for Spinal muscular atrophy (SMA). This training gathered clinicians to train and discuss SMA standardized outcome measures and work through current problems/challenges, to improve how these measures often tied to drug reimbursement are conducted.
MDC Announce Recipients of 2024 Neuromuscular Clinical and Translational Research Grants
Muscular Dystrophy Canada (MDC) recently announced the recipients of its annual Neuromuscular Research Grants competition. Through these grants, MDC is investing $900,000 into clinical and translational research projects.
SMA Outcome Measures Training for Physiotherapists and Occupational Therapists
To support the development and training on validated NMD outcome measures we are pleased to provide opportunities for physiotherapists and occupational therapists to attend training sessions for outcome measures.
Congratulations to the 2024 NMD4C Early Career Awards Recipients
We are excited to announce the recipients of the 2024 NMD4C Early Career Awards! This is the second year of our annual award program, celebrating excellence and contribution to the neuromuscular field from early career investigators across both clinical and basic science streams.